From: Hammersla, Ann (NIH/OD) [E] [/O=NIH/OU=NIHEXCHANGE/CN=RECIPIENTS/CN=HAMMERSLAA]

Sent: 4/24/2017 7:24:20 PM

To: Rohrbaugh, Mark (NIH/OD) [E] [/O=NIH/OU=NIHEXCHANGE/cn=OD/cn=ROHRBAUM]

Subject: RE: WF 357204 - Response Creation due 5/1

FC as recommended by ML

From: Rohrbaugh, Mark (NIH/OD) [E] Sent: Monday, April 24, 2017 3:23 PM

To: Hammersla, Ann (NIH/OD) [E] <hammerslaa@mail.nih.gov>

Subject: RE: WF 357204 - Response Creation due 5/1

Exec Sec asks who should sign it.

b5

From: Hammersla, Ann (NIH/OD) [E] Sent: Monday, April 24, 2017 3:15 PM

To: Rohrbaugh, Mark (NIH/OD) [E] < RohrBauM@OD.NIH.GOV >

Subject: RE: WF 357204 - Response Creation due 5/1

Thanks. I have not received this yet. Ann

From: Rohrbaugh, Mark (NIH/OD) [E] Sent: Monday, April 24, 2017 2:54 PM

To: Hammersla, Ann (NIH/OD) [E] < hammerslaa@mail.nih.gov >

Subject: FW: WF 357204 - Response Creation due 5/1

In case you did not get it through ES yet...

From: Plude, Denise (NIH/OD) [E] Sent: Monday, April 24, 2017 2:52 PM

To: Rohrbaugh, Mark (NIH/OD) [E] < RohrBauM@OD.NIH.GOV>

Cc: Wertz, Jennifer (NIH/OD) [E] < wertzj@od.nih.gov > **Subject:** WF 357204 - Response Creation due 5/1

Work Folder: WF 357204

Process: Response Creation

Program Analyst: Hurlebaus, Lisa (NIH/OD) [E]

Due Date: May 01, 2017

WF Subject: OS assignment. KEI & UACT write about the prostate cancer drug, Xtandi (enzalutamide). Asks the Government to reconsider the decision not to use the 'march-in' rights, under the Bayh-Dole Act, for this excessively-priced drug. (AS-760889)

IC: od osp

From: Goldman, Andrew To: Price, TomMattis, Jim

Remarks: OS assignment. Note to OER & OSP: Please work together to prepare Direct Reply response. You should decide/recommend who should sign draft response (Dr. Lauer or Dr. Wolinetz; or someone else?). Please provide draft response to Exec Sec in DDRMS by 12:00pm, Monday, May 1, for OD clearances. Thanks very much, Lisa Hurlebaus